 Crinetics Pharmaceuticals NASDAQ:CRNXs stock had its buy rating reissued by HC Wainwright in a research note issued on Friday, TipRanks reports. They currently have a 35.00 price objective on the stock. HC Wainwrights target price would indicate a potential upside of 165.35 from the stocks current price. A number of other equities research analysts have ... 